{"schema_version":"secwatch.filing_event.v1","accession":"0001295947-25-000037","form_type":"8-K","ticker":"PBH","cik":"0001295947","company_name":"Prestige Consumer Healthcare Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.044581+00:00","generated_at":"2026-05-16T23:24:42.880328+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Prestige Consumer Q2 adj EPS $1.07 beats prior year; raises FY adj EPS guidance to $4.54-$4.58","bullets":["Q2 revenue $274.1M (-3.4% YoY); diluted EPS $0.86 vs $1.09; adjusted EPS $1.07.","Raises FY2026 adjusted diluted EPS outlook to $4.54-$4.58 (high end of prior range).","Repurchased ~1.1M shares in Q2 for $75M; cumulative 1.6M shares in H1 for $109.8M.","Clear Eyes supply constraints drove OTC revenue decline; expects improvement in H2 via capacity rebuild.","Free cash flow guidance reaffirmed at $245M+; covenant leverage 2.4x."],"urls":{"canonical":"https://secwatch.observer/filing/0001295947-25-000037","json":"https://secwatch.observer/filing/0001295947-25-000037.json","markdown":"https://secwatch.observer/filing/0001295947-25-000037.md","text":"https://secwatch.observer/filing/0001295947-25-000037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1295947/000129594725000037/0001295947-25-000037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1295947/000129594725000037/pbh-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:24:42.880328+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}